Australian managed entry scheme: A new manageable process for the reimbursement of new medicines?

Value in Health

Volumn 15, Issue 3, 2012, Pages 586-590

  Wonder, Michael ^a   Backhouse, Martin E ^a   Sullivan, Sean D ^b  

^a University of Washington ^*

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Australia; decision making

Indexed keywords

ARTICLE; AUSTRALIA; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG SAFETY; GOVERNMENT; HEALTH CARE ACCESS; HUMAN; MANAGED ENTRY SCHEME; MANAGEMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT;

AUSTRALIA; COST-BENEFIT ANALYSIS; DECISION MAKING, ORGANIZATIONAL; MANAGED CARE PROGRAMS; PHARMACEUTICAL PREPARATIONS; REIMBURSEMENT MECHANISMS;

EID: 84861146325     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.02.004     Document Type: Article

References (19)

1. J. Golec, J.A. Vernon Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms Pharmacoeconomics 28 2010 615 628
2. Australian Government, Department of Health and Ageing Memorandum of understanding between the Commonwealth of Australia and Medicines Australia http://www.pbs.gov.au/info/news/2010/06/memorandum-of-understanding [Accessed February 15, 2012]
3. Australian Government, Department of Health and Ageing About the PBS http://www.pbs.gov.au/info/about-the-pbs [Accessed February 15, 2012]
4. Australian Government, Department of Health and Ageing National Medicines Policy http://www.health.gov.au/internet/main/publishing.nsf/Content/ National+Medicines+Policy-1 [Accessed February 15, 2012]
5. Australian Government, Department of Health and Ageing Guidelines for preparing submissions to the PBAC - December 2008 http://www.health.gov.au/ internet/main/publishing.nsf/content/pbacguidelines-index [Accessed February 15, 2012]
6. Australian Government, Department of Health and Ageing Listing medicines on the PBS http://www.health.gov.au/internet/main/publishing.nsf/Content/health- pbs-general-list-on-pbac.htm-copy2 [Accessed February 15, 2012]
7. Australian Government, Department of Health and Ageing Memorandum of understanding with Medicines Australia http://www.pbs.gov.au/info/industry/ useful-resources/memorandum September 2010 [Accessed February 15, 2012]
8. Australian Government, Department of Health and Ageing Framework for the introduction of a managed entry scheme for submissions to the Pharmaceutical Benefits Advisory Committee http://www.pbs.gov.au/info/publication/factsheets/ shared/framework-for-introduction-of-managed-entry-scheme-for-PBAC-submissions [Accessed February 15, 2012]
9. M. Backhouse, M. Wonder, E. Hornby Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study Value Health 14 2011 608 615
10. Australian Government, Pharmaceutical Benefits Pricing Authority Annual report for the year ended 30 June 2010 http://www.health.gov.au/internet/main/ publishing.nsf/Content/health-pbs-general-pricing-pbparpt.htm [Accessed February 15, 2012]
11. Australian Government, Department of Health and Ageing Guidelines for deeds of agreement http://www.pbs.gov.au/info/industry/listing/elements/deeds- agreement [Accessed February 15, 2012]
12. Australian Government, Department of Health and Ageing Public summary documents explained http://www.health.gov.au/internet/main/publishing.nsf/ Content/pbac-psd-psds-explained [Accessed February 15, 2012]
13. Generic Medicines Industry Association Politicians must safeguard Australians' access to necessary medicines Media release http://www.gmia.com.au/ 27-september-20.html September 27, 2010 [Accessed February 15, 2012]
14. F. Cervantes, J. Hernandez-Boluda, J. Steegman Imatinib mesylate therapy of chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients Haematologica 88 2003 117 122
15. R. Schrover, M. Adena, R. de Abreu Lourenco Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase Leuk Lymphoma 47 2006 1069 1081 (Pubitemid 44109057)
16. J.H. Wlodarczyk, L.G. Cleland, A.M. Keogh Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing Pharmacoeconomics 24 2006 903 915 (Pubitemid 44338300)
17. J. Wlodarczyk, C.M. Reid, G. Pater Funding linked to ongoing research: impact of the bosentan patient registry on pricing in Australia Value Health 14 2011 961 963
18. Australian Government, Department of Health and Ageing Feedback sought by the Pharmaceutical Benefits Advisory Committee on technical working group reports http://www.health.gov.au/internet/main/publishing.nsf/Content/Feedback- PBAC-March09 [Accessed February 15, 2012]
19. Australian Government, Department of Health and Ageing Cost recovery for evaluation and listing on the Pharmaceutical Benefits Scheme (PBS) and National Immunisation Program (NIP) http://www.pbs.gov.au/info/publication/factsheets/ shared/2009-11-01-Consumer-And-Health-Professional-Cost-Recovery-FAQ [Accessed February 15, 2012]